On August 1, 2016 Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"), reported that a poster presentation titled "Intralesional rose bengal for stage III and IV melanoma" is to be presented at the European Society for Medical Oncology 2016 Congress on October 9, 2016, in Hall E of the Bella Center in Copenhagen, Denmark (Press release, Provectus Pharmaceuticals, AUG 1, 2016, View Source [SID:1234514149]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ESMO’s Scientific Committee accepted the abstract for this poster presentation and further details can be found at View Source – 2z95v (Abstract 1158TiP).

In addition, the abstract will be published in the ESMO (Free ESMO Whitepaper) 2016 Congress Abstract Book, a supplement to the official ESMO (Free ESMO Whitepaper) journal, Annals of Oncology. ESMO (Free ESMO Whitepaper) has not yet announced the final publication number. The ESMO (Free ESMO Whitepaper) 2016 Congress will be held in Copenhagen, Denmark, from October 7-11, 2016.

Provectus believes the poster itself will be available online following the final session of the Congress.

About ESMO (Free ESMO Whitepaper)

ESMO is the leading European professional organization for medical oncology. With more than 13,000 members representing oncology professionals from over 130 countries, ESMO (Free ESMO Whitepaper) is the society of reference for oncology education and information. For more information, visit: View Source